Cari Gallman
Known title: EVP, General CounselCIK: 0001995058
Associated companies
Transaction History
| BMY | ▲ Buy | Option Exercise | 4,559 | $0 | 10/2/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,332 | $143K | 10/2/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 543 | $35K | 8/1/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,061 | $0 | 8/1/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 912 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Other | 102 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Other | 94 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,354 | $81K | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 415 | $25K | 3/10/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 867 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 396 | $24K | 3/10/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,201 | $0 | 3/10/2026 | View on chart |
| BMY | ▼ Sell | Other | 2,554 | $0 | 3/10/2026 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,558 | $0 | 10/2/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,332 | $107K | 10/2/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,061 | $0 | 8/1/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 543 | $24K | 8/1/2025 | View on chart |
| BMY | ▼ Sell | Other | 24 | $0 | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 349 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 118 | $7K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 910 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 159 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 272 | $17K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 867 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 148 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 260 | $16K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,462 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 2,014 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,290 | $81K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,558 | $0 | 10/2/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,648 | $89K | 10/2/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 1,061 | $0 | 8/1/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 384 | $18K | 8/1/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 105 | $6K | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 60 | $0 | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 349 | $0 | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 318 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 50 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 97 | $5K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 2,094 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 729 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 494 | $27K | 3/10/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus
Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.